Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 52 of 103, showing 5 Applications out of 512 total, starting on record 256, ending on 260

# Protocol No Study Title Investigator(s) & Site(s)

256.

ECCT/12/09/02   Reduction of EArly mortaLITY in adults and children
    Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Wellcome Trust Research Programme (Kilifi county)
 
View

257.

ECCT/16/08/01   A5349/TBTC S31
    A5349/TBTC S31 “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial”   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

258.

ECCT/23/05/06   Sildenafil citrate to improve
    Sildenafil citrate to improve maternal and neonatal outcomes in low-resource settings:    a randomized feasibility trial   
Principal Investigator(s)
1. Nora Switchenko
Site(s) in Kenya
NAKURU COUNTY REFERRAL AND TEACHING HOSPITAL
 
View

259.

ECCT/21/09/08   GBT133_Inclacumab Open-Label
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Bernhards Ragama Ogutu
3. Videlis N Nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
View

260.

ECCT/22/04/01   GBT Open Label inclacumab Ph3
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Prof Jessie N Githanga
4. Videlis N Nduba
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
 
View